**Background**
The androgen receptor (AR) is a nuclear receptor that plays a critical role in the development of male reproductive tissues and is a primary driver in the progression of prostate cancer. In many cases of prostate cancer, the tumor becomes resistant to conventional androgen deprivation therapy, leading to the development of castration-resistant prostate cancer (CRPC). Consequently, the development of potent AR inhibitors and degraders has become a focal point in oncology research. Proteolysis-targeting chimeras (PROTACs) have emerged as a revolutionary approach, utilizing the intracellular ubiquitin-proteasome system to selectively degrade target proteins rather than simply inhibiting their activity. By recruiting an E3 ubiquitin ligase to the target protein, PROTACs can achieve more complete protein depletion and overcome resistance mechanisms. In this context, we will introduce a potent ligand used in the synthesis of AR degraders – AR antagonist 1.
**Definition**
AR antagonist 1 (compound 29) hydrochloride is a potent androgen receptor (AR) antagonist with a molecular formula of C15H20Cl2N2O. It serves as a critical ligand for the target protein in the construction of highly efficient PROTACs.
**In Vitro Studies**
According to the AR antagonist 1 description, this compound is utilized as the target ligand for the synthesis of ARD-266, a highly potent VHL E3 ligase-based AR PROTAC degrader. In terms of AR antagonist 1 in vitro activity, the compound exhibits micromolar binding affinity to its E3 ligase complex. This specific binding profile allows it to be successfully employed in the design of PROTACs that exploit the recruitment of the VHL protein to the androgen receptor. The resulting PROTAC, ARD-266, leverages the dual-ligand system—consisting of the AR antagonist 1 ligand and a VHL E3 ligase ligand connected by a linker—to induce the selective ubiquitination and subsequent proteasomal degradation of the AR protein. In conclusion, AR antagonist 1 is a potent AR antagonist and an essential building block for the development of efficient AR-targeting PROTAC degraders.
Keywords
AR antagonist 1, 1818885-55-0, AR antagonist1, AR antagonist-1, Ligands for E3 Ligase, Ligands for Target Protein for PROTAC, Androgen Receptor, E3 ligase-recruiting Moiety, Target Protein-binding Moiety, PROTAC, Linker, tumor, cancer, LNCaP, VCaP
References